"A US Food and Drug Administration (FDA) advisory panel gave near-unanimous support for approval of the Absorb GT1 bioresorbable vascular scaffold (BVS) system (Abbott Vascular).
If approved, Absorb would be the first drug-eluting coro"...
Inform patients about the common adverse effects of VAPRISOL including infusion site effects (edema, erythema, pain, and phlebitis), pyrexia, hypokalemia, headache, orthostatic hypotension and potential for overly rapid increase in serum sodium which can cause serious neurologic sequelae. Instruct patients to inform their healthcare provider if they develop any unusual symptoms, or if any known symptom persists or worsens, with special attention to potential manifestations of osmotic demyelination syndrome.
Ask patients about what other medications they are currently taking with VAPRISOL, including over-thecounter medications.
Advise women not to breastfeed during treatment with VAPRISOL [see Use in Specific Populations].
Last reviewed on RxList: 11/7/2016
This monograph has been modified to include the generic and brand name in many instances.
Additional Vaprisol Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.